This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Broom, I. Search for Related Content Social Bookmarking                         What's this?

Review: Thinking around abdominal obesity and cardiovascular risk

Robert Gordon University and NHS Grampian, St Andrew Street, Aberdeen, AB25 1HG, Scotland, ext.broom{at}rgu.ac.uk

Obesity, particularly intra-abdominal (visceral) obesity, is a leading cause of cardiovascular disease (CVD), insulin resistance, type 2 diabetes, dyslipidaemia, inflammation and thrombosis. A useful indicator for visceral fat is waist circumference, which is associated with all-cause mortality. Pro-inflammatory adipokines play a causal role in the development of pathologies associated with insulin resistance, type 2 diabetes and CVD. In addition to established anti-obesity therapies, namely orlistat and sibutramine, a new type of agent that inhibits the cannabinoid receptor (CB1) is advanced in development to reduce appetite and act predominantly against intra-abdominal adiposity.

Key Words: abdominal obesity • metabolic syndrome • visceral fat • waist circumference • cardiometabolic risk.

The British Journal of Diabetes & Vascular Disease, Vol. 6, No. 2, 58-61 (2006)
DOI: 10.1177/14746514060060020301


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?